Standard BioTools Inc. (LAB) — Financial statements
Income statement, balance sheet, and cash flow for Standard BioTools Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 85↓51.1% | 174↑64.0% | 106↑8.6% | 98↓25.0% | 131 | |
| Cost of Revenue | 43↓52.5% | 90↑61.3% | 56↓8.2% | 61↓0.5% | 61 | |
| Gross Profit | 43↓49.5% | 84↑67.0% | 50↑36.2% | 37↓46.6% | 69 | |
| Operating Expenses | ||||||
| R&D Expenses | 26↓58.4% | 62↑140.5% | 26↓30.6% | 37↓1.5% | 38 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 110↓29.8% | 157↑78.9% | 88↓14.4% | 102↑3.4% | 99 | |
| Other Expenses | 0.00↓100.0% | 40↑198.5% | 14↓0.2% | 14 | 0.00 | |
| Operating Expenses | 136↓47.6% | 259↑104.2% | 127↓17.1% | 153↑12.0% | 137 | |
| Total Costs & Expenses | 179↓48.9% | 350↑91.1% | 183↓14.6% | 214↑8.1% | 198 | |
| Operating Results | ||||||
| Operating Income | -93↑46.8% | -175↓128.8% | -77↑34.1% | -116↓72.3% | -67 | |
| Depreciation & Amortization | 7↓58.6% | 17↑11.1% | 15↑1.0% | 15↓3.5% | 16 | |
| EBITDA | -86↑26.9% | -118↓116.9% | -54↑68.6% | -174↓292.1% | -44 | |
| EBIT | -93↑30.9% | -135↓93.9% | -70↑63.1% | -189↓215.2% | -60 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓45.8% | 17↑1579.9% | 1↑147.7% | -2↑44.9% | -4 | |
| Interest Income | 9↓54.6% | 20↑262.5% | 6↑150.3% | 2 | 0.00 | |
| Interest Expense | 0.03↓99.2% | 3↓27.4% | 5↑5.4% | 4↑13.3% | 4 | |
| Non-Operating Income | 0.00↑100.0% | -40↓477.9% | -7↓109.6% | 72↑1049.8% | -8 | |
| Other Income / Expenses | -3↓109.2% | 37↑1441.1% | 2↑103.1% | -77↓2119.6% | 4 | |
| Income Before Tax | -97↑30.1% | -138↓86.4% | -74↑61.5% | -193↓203.1% | -64 | |
| Income Tax Expense | -38↓6710.1% | 0.57↑26.8% | 0.45↑116.0% | -3↑36.0% | -4 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -59↑57.6% | -139↓86.0% | -75↑60.7% | -190↓220.9% | -59 | |
| Net Income from Discontinued Operations | -16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -75↑46.1% | -139↓86.0% | -75↑60.7% | -190↓220.9% | -59 | |
| Bottom-Line Net Income | -75↑59.5% | -185↓147.7% | -75↑60.7% | -190↓220.9% | -59 | |
| EPS (Basic) | -0.20↑61.5% | -0.52↑44.7% | -0.94↑61.3% | -2.43↓211.5% | -0.78 | |
| EPS (Diluted) | -0.20↑61.5% | -0.52↑44.7% | -0.94↑61.3% | -2.43↓211.5% | -0.78 | |
| Weighted Average Shares | 382↑8.2% | 353↑345.5% | 79↑1.1% | 78↑3.3% | 76 | |
| Weighted Average Diluted Shares | 382↑8.2% | 353↑345.5% | 79↑1.1% | 78↑3.3% | 76 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.